Clinical Trial: Study of the Safety and Immunogenicity of Catch-up Vaccination with a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06838000) titled 'Study of the Safety and Immunogenicity of Catch-up Vaccination with a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents' on Oct. 10, 2024.

Brief Summary: The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).

Study Start Date: March 04

Study Type: INTERVENTIONAL

Condition: Pneumococcal Infections

Intervention: BIOLOGICAL: PC...